Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 93 | 0.85 |
| pathways Reactome | 33 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 6918
Sealed predictions
- CCNH in dopamine neurons, braak+0.25 (p 0.508) → +0.63 (p 0.067)receipt 6926
Swarm cases
receipt 6926: CCNH in dopamine neurons, braak
- power
- full sample +0.47 (p 0.047, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.50 (p 0.036, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.032, n 18). not the mix.
- skeptic
- leave-one-out range +0.41 to +0.56, sign flips 0; without severely affected donors +0.47 (p 0.047, n 18). robust.
- cell type
- strongest in oligodendrocytes: +0.66 (p 0.0031, n 18) vs +0.47 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCNH in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CCNH · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.55 p 0.051 (needs p < 3.0e-4)
Receipts
loading the receipts